文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

偏头痛发作期启动依替尼单抗静脉治疗的随机临床试验

Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

这项3期多中心双盲随机对照试验纳入480例偏头痛患者,在偏头痛发作期间静脉给予依替尼单抗100 mg或安慰剂。依替尼单抗组头痛疼痛缓解和最常见困扰症状消失的中位时间均显著短于安慰剂组,2小时和4小时缓解率更高,24小时内急救药物使用更少,不良事件发生率与安慰剂相当。

要点

  • 偏头痛发作期静脉给予依替尼单抗100 mg可加快头痛缓解。
  • 依替尼单抗组2小时无痛率23.5%,安慰剂组12.0%。
  • 依替尼单抗组24小时急救药物使用率31.5%,低于安慰剂组59.9%。

核心结论

  • 在适合预防性治疗的偏头痛患者中,发作期静脉给予依替尼单抗相比安慰剂可缩短头痛和困扰症状缓解时间。
  • 偏头痛发作期给予依替尼单抗的可行性及与替代治疗的比较尚待确立。

研究设计与样本

  • 3期、多中心、平行组、双盲、随机、安慰剂对照试验,2019年11月4日至2020年7月8日在美国和格鲁吉亚的47个中心进行。
  • 纳入18-75岁、偏头痛病史超过1年且筛选前3个月每月偏头痛4-15天的患者,在中重度偏头痛发作期间治疗。
  • 依替尼单抗100 mg组238例,安慰剂组242例,均在发作后1-6小时内静脉给药。
  • 480例随机治疗患者平均年龄44岁,84%为女性,476例完成研究。

主要发现

  • 依替尼单抗组与安慰剂组头痛无痛中位时间分别为4小时和9小时(风险比1.54,P<.001)。
  • 依替尼单抗组与安慰剂组最常见困扰症状消失中位时间分别为2小时和3小时(风险比1.75,P<.001)。
  • 输注后2小时,依替尼单抗组和安慰剂组头痛无痛率分别为23.5%和12.0%(组间差11.6%,95%CI 4.78%-18.31%;OR 2.27,95%CI 1.39-3.72;P<.001)。
  • 输注后2小时,依替尼单抗组和安慰剂组最常见困扰症状消失率分别为55.5%和35.8%(组间差19.6%,95%CI 10.87%-28.39%;OR 2.25,95%CI 1.55-3.25;P<.001)。
  • 24小时内急救药物使用率依替尼单抗组31.5%,安慰剂组59.9%(组间差-28.4%,95%CI -36.95%至-19.86%;OR 0.31,95%CI 0.21-0.45;P<.001)。

关键数值与推荐

  • 共同主要终点为头痛无痛时间和最常见困扰症状(恶心、畏光或畏声)消失时间。
  • 关键次要终点为输注开始后2小时头痛无痛率和最常见困扰症状消失率。
  • 其他次要终点包括输注后4小时头痛无痛率和困扰症状消失率及24小时内急救药物使用。
  • 治疗中出现不良事件发生率依替尼单抗组10.9%,安慰剂组10.3%;最常见为超敏反应(依替尼单抗2.1%,安慰剂0%)。
  • 未发生治疗中出现的严重不良事件。

临床怎么用

  • 对于符合预防性治疗指征的偏头痛患者,在发作期启动依替尼单抗静脉治疗可加速症状缓解并减少急救药物使用。
  • 用药后需关注超敏反应,试验中依替尼单抗组超敏反应发生率为2.1%。

局限性

  • 偏头痛发作期给予依替尼单抗的可行性及与替代治疗的比较尚待确立。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intravenous eptinezumab, an anti-calcitonin gene-related peptide antibody, is approved for migraine prevention in adults. It has established onset of preventive efficacy on day 1 after infusion. OBJECTIVE: To evaluate the efficacy of and adverse events related to eptinezumab when initiated during a migraine attack. DESIGN, SETTING, AND PARTICIPANTS: Phase 3, multicenter, parallel-group, double-blind, randomized, placebo-controlled trial conducted from November 4, 2019, to July 8, 2020, at 47 sites in the United States and the country of Georgia. Participants (aged 18-75 years) with a greater than 1-year history of migraine and migraine on 4 to 15 days per month in the 3 months prior to screening were treated during a moderate to severe migraine attack. INTERVENTIONS: Eptinezumab, 100 mg (n = 238), or placebo (n = 242), administered intravenously within 1 to 6 hours of onset of a qualifying moderate to severe migraine. MAIN OUTCOMES AND MEASURES: Co-primary efficacy end points were time to headache pain freedom and time to absence of most bothersome symptom (nausea, photophobia, or phonophobia). Key secondary end points were headache pain freedom and absence of most bothersome symptom at 2 hours after start of infusion. Additional secondary end points were headache pain freedom and absence of most bothersome symptom at 4 hours and use of rescue medication within 24 hours. RESULTS: Of 480 randomized and treated patients (mean age, 44 years; 84% female), 476 completed the study. Patients treated with eptinezumab vs placebo, respectively, achieved statistically significantly faster headache pain freedom (median, 4 hours vs 9 hours; hazard ratio, 1.54 [P < .001]) and absence of most bothersome symptom (median, 2 hours vs 3 hours; hazard ratio, 1.75 [P < .001]). At 2 hours after infusion, in the respective eptinezumab and placebo groups, headache pain freedom was achieved by 23.5% and 12.0% (between-group difference, 11.6% [95% CI, 4.78%-18.31%]; odds ratio, 2.27 [95% CI, 1.39-3.72]; P < .001) and absence of most bothersome symptom by 55.5% and 35.8% (between-group difference, 19.6% [95% CI, 10.87%-28.39%]; odds ratio, 2.25 [95% CI, 1.55-3.25]; P < .001). Results remained statistically significant at 4 hours after infusion. Statistically significantly fewer eptinezumab-treated patients used rescue medication within 24 hours than did placebo patients (31.5% vs 59.9%, respectively; between-group difference, -28.4% [95% CI, -36.95% to -19.86%]; odds ratio, 0.31 [95% CI, 0.21-0.45]; P < .001). Treatment-emergent adverse events occurred in 10.9% of the eptinezumab group and 10.3% of the placebo group; the most common was hypersensitivity (eptinezumab, 2.1%; placebo, 0%). No treatment-emergent serious adverse events occurred. CONCLUSIONS AND RELEVANCE: Among patients eligible for preventive migraine therapy experiencing a moderate to severe migraine attack, treatment with intravenous eptinezumab vs placebo shortened time to headache and symptom resolution. Feasibility of administering eptinezumab treatment during a migraine attack and comparison with alternative treatments remain to be established. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04152083.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Winner PK, McAllister P, Chakhava G, et al. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial. JAMA. 2021. PMID: 34128999. doi:10.1001/jama.2021.7665

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。